Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic activity of a hematopoietic stem cell-delivered cell-penetrating frataxin in Friedreich's ataxia models.

Cell reports. Medicine·2026
Same author

Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Selecting Novel Retino-tropic AAV Capsids by Directed Evolution.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.

Blood·2026
Same author

Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.

Obstetrical & gynecological survey·2025
Same author

Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.

Obstetrical & gynecological survey·2025

Related Experiment Video

Updated: Jun 5, 2025

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants

Published on: October 18, 2022

4.4K

Tailoring capsid-directed evolution technology for improved AAV-mediated CAR-T generation.

Adrian Westhaus1, Elena Barba-Sarasua2, Yuyan Chen3

  • 1Translational Vectorology Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia; Infection, Immunity and Inflammation Research and Teaching Department, Great Ormond Street Institute of Child Health, University College, London, UK.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|December 14, 2024
PubMed
Summary
This summary is machine-generated.

Researchers developed a new AAV capsid evolution platform to improve CAR T-cell therapy. This platform identified novel AAVs, AAV-T1 and AAV-T2, enhancing CAR construct integration for more effective leukemia and brain tumor treatments.

Keywords:
AAVCAR-TT-cell engineeringcancercancer gene therapycell therapydirected evolutiongene therapyhigh-grade gliomasynthetic biology

More Related Videos

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
21:55

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling

Published on: April 2, 2012

28.4K
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.3K

Related Experiment Videos

Last Updated: Jun 5, 2025

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants

Published on: October 18, 2022

4.4K
Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
21:55

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling

Published on: April 2, 2012

28.4K
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.3K

Area of Science:

  • Gene Therapy
  • Immunotherapy
  • Molecular Biology

Background:

  • Chimeric antigen receptor (CAR) T cell (CAR-T) therapies are used for certain leukemias.
  • Integrating CAR into the T cell receptor alpha constant (TRAC) locus enhances CAR expression using endogenous elements.
  • Adeno-associated viral (AAV) vectors, specifically AAV6, have been used for CAR construct delivery.

Purpose of the Study:

  • To develop a novel AAV capsid directed evolution platform for improved CAR gene editing.
  • To identify novel AAV capsid variants for more efficient CAR construct integration into the TRAC locus.
  • To enhance the efficacy of CAR T-cell therapy through improved vector delivery.

Main Methods:

  • Developed a directed evolution platform for AAV capsid selection.
  • Selected novel AAV capsid variants capable of efficient gene editing in primary T cells.
  • Evaluated the efficiency of CAR construct integration into the TRAC locus using new AAV variants.

Main Results:

  • Identified novel AAV capsids, AAV-T1 and AAV-T2, demonstrating superior editing efficiency in T cells compared to AAV6.
  • Achieved a 5-fold improvement in on-target CAR knockin efficiency.
  • Enabled a 5-fold reduction in vector dose, leading to highly cytolytic T cells against a brain tumor cell line.

Conclusions:

  • The novel AAV capsid platform successfully identified enhanced AAV variants for CAR T-cell therapy.
  • AAV-T1 and AAV-T2 significantly improve targeted gene editing for CAR integration.
  • These advancements hold promise for more effective CAR T-cell treatments for leukemias and potentially other cancers.